Nagendran Sukumar 4

What Happened
Nagendran Sukumar, President and Head of R&D and a director at Taysha Gene Therapies (TSHA), sold a total of 116,050 shares in two open-market sell transactions to satisfy tax withholding on vested restricted stock units. He sold 89,132 shares on 2026-01-23 at a weighted average price of $4.75 for proceeds of $423,377, and 26,918 shares on 2026-01-26 at a weighted average price of $4.61 for proceeds of $124,092 — total proceeds about $547,469. These are sales (not purchases) and appear to be routine sell-to-cover tax-withholding transactions.

Key Details

• Transaction dates: 2026-01-23 (89,132 shares) and 2026-01-26 (26,918 shares).
• Weighted average prices reported: $4.75 (Jan 23) and $4.61 (Jan 26).
• Price ranges: Jan 23 sales ranged $4.635–$4.99; Jan 26 sales ranged $4.505–$4.715. The filer can provide a per-price breakdown on request (see footnotes).
• Total shares sold: 116,050; total proceeds: ≈ $547,469.
• Reason: Footnote indicates sales were mandatory "sell-to-cover" transactions to satisfy income tax liabilities from RSU vesting (tax withholding).
• Filing: Form 4 filed 2026-01-27 covering the 2026-01-23/01-26 transactions. The Form 4 was filed within the typical 2-business-day window (not reported as late).
• Shares owned after transaction: not disclosed in the supplied summary of the filing.

Context
These were sales to cover taxes on restricted stock unit vesting (routine, tax-related), not open-market purchases that might indicate an insider adding to a position. The transactions are coded as sales (S) and noted for tax withholding (footnote F1). For retail investors, such sell-to-cover transactions generally should not be interpreted as a standalone negative signal about company prospects.